Evidence map›Paper›PMID 38397020›Full record

ArticleInternational journal of molecular sciences2024

Anserine, a Histidine-Containing Dipeptide, Suppresses Pressure Overload-Induced Systolic Dysfunction by Inhibiting Histone Acetyltransferase Activity of p300 in Mice.

Yoichi Sunagawa, Ryosuke Tsukabe, Yudai Irokawa, Masafumi Funamoto, Yuto Suzuki, Miho Yamada, Satoshi Shimizu, Yasufumi Katanasaka, Toshihide Hamabe-Horiike, Yuto Kawase and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Current Research for Heart Disease Biology and Therapeutics.International journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Yoichi SunagawaDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.ORCID 0000-0002-4516-2308
Ryosuke TsukabeDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.
Yudai IrokawaDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.
Masafumi FunamotoDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.
Yuto SuzukiDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.
Miho YamadaDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.
Satoshi ShimizuDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.
Yasufumi KatanasakaDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.ORCID 0000-0002-1755-2157
Toshihide Hamabe-HoriikeDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.ORCID 0000-0001-9075-9982
Yuto KawaseDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.
Ryuya NarutaDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.
Kana ShimizuDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.
Kiyoshi MoriShizuoka General Hospital, Shizuoka 420-8527, Japan.ORCID 0000-0002-7285-8351
Ryota HosomiLaboratory of Food and Nutritional Sciences, Faculty of Chemistry, Materials and Bioengineering, Kansai University, Osaka 564-8680, Japan.ORCID 0000-0003-2183-1746
Maki KomiyamaDivision of Translational Research, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan.ORCID 0000-0002-8827-3315
Koji HasegawaDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.
Tatsuya MorimotoDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.ORCID 0000-0002-7054-4447
University of Shizuoka · JPKansai University · JPKyoto Medical Center · JP

Funding

Japan Science and Technology Agency 19K16396Japan Science and Technology Agency 20K07070Japan Science and Technology Agency 21K08069Japan Science and Technology Agency 23K14445Nutrition and Food Science Fund of the Japan Society of Nutrition and Food Science Y.SunagawaToyo Institute of Food Technology Y.Sunagawa
6 · The paper itself

Abstract

Anserine, an imidazole dipeptide, is present in the muscles of birds and fish and has various bioactivities, such as anti-inflammatory and anti-fatigue effects. However, the effect of anserine on the development of heart failure remains unknown. We cultured primary cardiomyocytes with 0.03 mM to 10 mM anserine and stimulated them with phenylephrine for 48 h. Anserine significantly suppressed the phenylephrine-induced increases in cardiomyocyte hypertrophy, ANF and BNP mRNA levels, and histone H3K9 acetylation. An in vitro histone acetyltransferase (HAT) assay showed that anserine directly suppressed p300-HAT activity with an IC

Indexed as

AnserineCardiomyopathiesHeart FailureMyocytes, Cardiacp300-CBP Transcription FactorsAcetylationAnimalsCardiomegalyEnzyme InhibitorsHistonesHumansMaleMiceMice, Inbred C57BLPhenylephrineAnserineEnzyme InhibitorsHistonesp300-CBP Transcription FactorsPhenylephrineanserinecardiomyocyte hypertrophyheart failurehistone acetyltransferase activityp300pressure overload

Identifiers

PMID38397020
PMCPMC10889817
OpenAlexW4391883524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.